Cargando…

The use of matrigel has no influence on tumor development or PET imaging in FaDu human head and neck cancer xenografts

BACKGROUND: In preclinical research Matrixgel(TM) Basement Membrane Matrix (MG) is used frequently for the establishment of syngeneic and xenograft cancer models. Limited information on its influence on parameters including; tumor growth, vascularization, hypoxia and imaging characteristics is curre...

Descripción completa

Detalles Bibliográficos
Autores principales: Fliedner, Frederikke P., Hansen, Anders E., Jørgensen, Jesper T., Kjær, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712613/
https://www.ncbi.nlm.nih.gov/pubmed/26762341
http://dx.doi.org/10.1186/s12880-016-0105-4
_version_ 1782410099785990144
author Fliedner, Frederikke P.
Hansen, Anders E.
Jørgensen, Jesper T.
Kjær, Andreas
author_facet Fliedner, Frederikke P.
Hansen, Anders E.
Jørgensen, Jesper T.
Kjær, Andreas
author_sort Fliedner, Frederikke P.
collection PubMed
description BACKGROUND: In preclinical research Matrixgel(TM) Basement Membrane Matrix (MG) is used frequently for the establishment of syngeneic and xenograft cancer models. Limited information on its influence on parameters including; tumor growth, vascularization, hypoxia and imaging characteristics is currently available. This study evaluates the potential effect of matrigel use in a human head and neck cancer xenograft model (FaDu; hypopharyngeal carcinoma) in NMRI nude mice. The FaDu cell line was chosen based on its frequent use in studies of cancer imaging and tumor microenvironment. METHODS: NMRI nude mice (n = 34) were divided into two groups and subcutaneously injected with FaDu cells in medium either including (+MG) or excluding matrigel (−MG). In sub study I seven mice from each group (+MG, n = 7; −MG, n = 7) were (18)F- fluorodeoxyglucose ((18)F-FDG) PET/CT scanned on Day 5, 8, 12, 15, and 19. In sub study II ten mice from each group (+MG, n = 10; −MG, n = 10) were included and tumors collected for immunohistochemistry (IHC) analysis of tumor microenvironment including; proliferation ratio, micro vessel density, average vessel area, hypoxia, nuclear density, and necrosis. Tumors for IHC were collected according to size (200–400 mm(3), 500–700 mm(3), 800–1100 mm(3)). RESULTS: FDG uptake and tumor growth was statistically compatible for the tumors established with or without MG. The IHC analysis on all parameters only identified a significantly higher micro vessel density for tumor size 500–700 mm(3) and 800–1100 mm(3) and average vessel area for tumor size 500–700 mm(3) in the −MG group. Comparable variations were observed for tumors of both the +MG and −MG groups. No difference in tumor take rate was observed between groups in study. CONCLUSIONS: Matrigel did not affect tumor growth or tumor take for the FaDu xenograft model evaluated. Tumors in the -MG group displayed increased angiogenesis compared to the +MG tumors. No difference in (18)F-FDG PET uptake for tumors of different groups was found. Based on these observations the influence of matrigel on tumor imaging and tumor microenvironment seems minor for this particular xenograft model.
format Online
Article
Text
id pubmed-4712613
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47126132016-01-15 The use of matrigel has no influence on tumor development or PET imaging in FaDu human head and neck cancer xenografts Fliedner, Frederikke P. Hansen, Anders E. Jørgensen, Jesper T. Kjær, Andreas BMC Med Imaging Research Article BACKGROUND: In preclinical research Matrixgel(TM) Basement Membrane Matrix (MG) is used frequently for the establishment of syngeneic and xenograft cancer models. Limited information on its influence on parameters including; tumor growth, vascularization, hypoxia and imaging characteristics is currently available. This study evaluates the potential effect of matrigel use in a human head and neck cancer xenograft model (FaDu; hypopharyngeal carcinoma) in NMRI nude mice. The FaDu cell line was chosen based on its frequent use in studies of cancer imaging and tumor microenvironment. METHODS: NMRI nude mice (n = 34) were divided into two groups and subcutaneously injected with FaDu cells in medium either including (+MG) or excluding matrigel (−MG). In sub study I seven mice from each group (+MG, n = 7; −MG, n = 7) were (18)F- fluorodeoxyglucose ((18)F-FDG) PET/CT scanned on Day 5, 8, 12, 15, and 19. In sub study II ten mice from each group (+MG, n = 10; −MG, n = 10) were included and tumors collected for immunohistochemistry (IHC) analysis of tumor microenvironment including; proliferation ratio, micro vessel density, average vessel area, hypoxia, nuclear density, and necrosis. Tumors for IHC were collected according to size (200–400 mm(3), 500–700 mm(3), 800–1100 mm(3)). RESULTS: FDG uptake and tumor growth was statistically compatible for the tumors established with or without MG. The IHC analysis on all parameters only identified a significantly higher micro vessel density for tumor size 500–700 mm(3) and 800–1100 mm(3) and average vessel area for tumor size 500–700 mm(3) in the −MG group. Comparable variations were observed for tumors of both the +MG and −MG groups. No difference in tumor take rate was observed between groups in study. CONCLUSIONS: Matrigel did not affect tumor growth or tumor take for the FaDu xenograft model evaluated. Tumors in the -MG group displayed increased angiogenesis compared to the +MG tumors. No difference in (18)F-FDG PET uptake for tumors of different groups was found. Based on these observations the influence of matrigel on tumor imaging and tumor microenvironment seems minor for this particular xenograft model. BioMed Central 2016-01-14 /pmc/articles/PMC4712613/ /pubmed/26762341 http://dx.doi.org/10.1186/s12880-016-0105-4 Text en © Fliedner et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Fliedner, Frederikke P.
Hansen, Anders E.
Jørgensen, Jesper T.
Kjær, Andreas
The use of matrigel has no influence on tumor development or PET imaging in FaDu human head and neck cancer xenografts
title The use of matrigel has no influence on tumor development or PET imaging in FaDu human head and neck cancer xenografts
title_full The use of matrigel has no influence on tumor development or PET imaging in FaDu human head and neck cancer xenografts
title_fullStr The use of matrigel has no influence on tumor development or PET imaging in FaDu human head and neck cancer xenografts
title_full_unstemmed The use of matrigel has no influence on tumor development or PET imaging in FaDu human head and neck cancer xenografts
title_short The use of matrigel has no influence on tumor development or PET imaging in FaDu human head and neck cancer xenografts
title_sort use of matrigel has no influence on tumor development or pet imaging in fadu human head and neck cancer xenografts
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712613/
https://www.ncbi.nlm.nih.gov/pubmed/26762341
http://dx.doi.org/10.1186/s12880-016-0105-4
work_keys_str_mv AT fliednerfrederikkep theuseofmatrigelhasnoinfluenceontumordevelopmentorpetimaginginfaduhumanheadandneckcancerxenografts
AT hansenanderse theuseofmatrigelhasnoinfluenceontumordevelopmentorpetimaginginfaduhumanheadandneckcancerxenografts
AT jørgensenjespert theuseofmatrigelhasnoinfluenceontumordevelopmentorpetimaginginfaduhumanheadandneckcancerxenografts
AT kjærandreas theuseofmatrigelhasnoinfluenceontumordevelopmentorpetimaginginfaduhumanheadandneckcancerxenografts
AT fliednerfrederikkep useofmatrigelhasnoinfluenceontumordevelopmentorpetimaginginfaduhumanheadandneckcancerxenografts
AT hansenanderse useofmatrigelhasnoinfluenceontumordevelopmentorpetimaginginfaduhumanheadandneckcancerxenografts
AT jørgensenjespert useofmatrigelhasnoinfluenceontumordevelopmentorpetimaginginfaduhumanheadandneckcancerxenografts
AT kjærandreas useofmatrigelhasnoinfluenceontumordevelopmentorpetimaginginfaduhumanheadandneckcancerxenografts